Among the 95 patients, 28 (29.5%) were younger than 60 years, 73 (76.8%) were male and 22 (23.3%) were female, 66 (69.5%) were former or current smokers, 91 (95.8%) were adenocarcinomas, 88 (92.6%) had ECOG PS score of 0–1, 52 (54.7%) had intrathoracic metastasis, six (6.3%) had liver metastasis, 33 (34.7%) had bone metastasis, 21 (22.1%) had brain metastasis, 23 (24.2%) were KRAS G12C, 42 (44.2%) were KRAS non-G12C, and 30 (31.6%) had unknown mutations. Here, KRAS is linked to bone metastasis.